期刊文献+

冠状动脉粥样硬化斑块的形成、发展和逆转 被引量:18

Formation,Progression and Regression in Coronary Atherosclerotic Plaque
原文传递
导出
摘要 冠状动脉粥样硬化斑块形成是冠心病的病理基础,贯穿疾病发生与进展的整个过程。近年来国内外大量关于动脉粥样硬化的研究证实,降脂治疗不仅能稳定斑块,甚至能“逆转斑块”。本文对冠状动脉粥样硬化斑块逆转的机制、临床证据、治疗策略的最新研究进展进行概述。 The formation of coronary atherosclerotic plaque is an important pathological basis for coronary heart disease,which runs through the overall process of the formation and progression of the disease.In recent years,a large number of studies on atherosclerosis at home and abroad have confirmed that lipid-lowering therapy can not only stabilize plaque,but also"reverse plaque".This article reviews the research progress of the mechanism,clinical evidence and treatment strategies of coronary atherosclerotic plaque regression.
作者 陈倍佳 洪李锋 李建军 CHEN Beijia;HONG Lifeng;LI Jianjun(Department of Cardiology,The Fifth Hospital in Wuhan,Wuhan 430050,China;National Center for Cardiovascular Diseases,Fuwai Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100037,China)
出处 《中国分子心脏病学杂志》 CAS 2022年第5期4873-4877,共5页 Molecular Cardiology of China
基金 武汉市科技计划项目(2020020601012315)。
关键词 冠状动脉疾病 动脉粥样硬化 斑块逆转 Coronary artery disease Atherosclerosis Plaque regression
  • 相关文献

参考文献4

二级参考文献24

  • 1Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
  • 2LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
  • 3Pedersen TR, Faergeman O, Kastelein J J, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowedng (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trial. JAMA. 2005;294:2437-2445.
  • 4Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. J Am Coll Cardiol. 2004;44:720-732.
  • 5Blankenhom DH, Azen SP, Kramsch DM, et al;MARS Research Group. Coronary angiographic changes with Iovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med.1993;119:969-976.
  • 6Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed be serial quantitaUve arteriography: the Canadian Coronary Atherosclerosis Intervention Trial(CCAIT). Circulation. 1994;89:959-968.
  • 7Jukema JW, Bruschke AV, van Boven A J, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
  • 8Pitt B, Mancini GB, Ellis SG, Rosrnan HS, Park J-S,McGovem ME. Pravastatin limitaUon of atherosclerosis in the coronary arteries (PLAC Ⅰ): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
  • 9Brown G, Albers J J, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
  • 10MAAS Study Group. Effect of simvastatin on coronary atheroma: the Multicentre Anti-atheroma Study( MAAS). Lancet. 1994;344:633 -638.

共引文献400

同被引文献209

引证文献18

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部